SLC5A5 and breast carcinoma: The success obtained in the treatment of DTC patients (disease-free and overall survival) has turned RAI into a potential therapeutic tool for other tumors that express NIS, such as breast cancer [12], ovarian cancer [11], and testicular carcinomas [10].